nmp
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2015 (NCT02468687)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1-methyl-2-pyrrolidinone
- 1-methyl-2-pyrrolidinone
- 1-methyl-2-pyrrolidinone
- 1-methyl-2-pyrrolidinone, 1-methyl-(14)c-labeled
- 1-methyl-2-pyrrolidinone, 2,3,4,5-(14)c-labeled
- 1-methyl-2-pyrrolidone
- 1-methyl-2-pyrrolidone
- 1-methyl-5-pyrrolidinone
- 1-methyl-5-pyrrolidinone
- 1-methylpyrrolidinone
- 1-methylpyrrolidinone
- methylpyrrolidone
- methylpyrrolidone
- methyl pyrrolidone
- methyl pyrrolidone
- methyl pyrrolidone
- n-methyl-2-pyrrolidinone
- n-methyl-2-pyrrolidone
- n-methyl-2-pyrrolidone
- n-methyl-2-pyrrolidone
- n-methylpyrrolidinone
- n-methylpyrrolidone
- n-methylpyrrolidone
- n-methylpyrrolidone
- n-methyl-pyrrolidone
- n-methyl-pyrrolidone
- n-methyl-pyrrolidone
- nmp
- nmp
- pharmasolve
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05106920 | N/A | Nov 3, 2021 | University of Seville |
| NCT04590443 | N/A | Oct 15, 2020 | University of Seville |
| NCT04347265 | N/A | Jun 1, 2020 | University of Seville |
| NCT02468687 | Phase 1 | Aug 1, 2015 | Melbourne Health, Peter MacCallum Cancer Centre |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Seville | Academic/Hospital | 3 | 3 | 1 | 2020 |
| Melbourne Health | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1